Loading company
CVRx, Inc.
CVRX · Nasdaq · ·
Next earnings: November 4, 2026
$2.64+1.5%Sep 29 close
- 1M
- -10.5%
- 6M
- -70.2%
- 1Y
- -67.3%
- 5Y
- -83.7%
CVRX · Nasdaq · ·
Next earnings: November 4, 2026
$2.64+1.5%Sep 29 close
CVRx, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $15.7M | $13.6M | +15.57% |
| Profit | -$14M | -$14.7M | +4.70% |
| Profit per share | -$0.53 | -$0.57 | +7.02% |
| Free Cash Flow | -$8.9M | -$8M | -11.18% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from CVRx, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
CVRx, Inc. has no earnings call transcript available.